Addendum
Nivolumab (melanoma, adjuvant) - Addendum to Commission A21-39
Report documents
-
Addendum
Nivolumab (melanoma, adjuvant) - Addendum to Commission A21-39
Dossier assessment
Indication:
Adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection
Result of dossier assessment:
Unchanged after addendum:
- Stage IIIB/C and IV disease: hint of non-quantifiable added benefit.
- Stage IIIA disease: added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2021-09-16 A G-BA decision was published.
Project details
- Project no.
- A21-106
- Commission
- Commission awarded on 10.08.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed